Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

March 2022 | 49 pages | ID: C1C872D10D2BEN
Global Markets Direct

Abstracts

Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Complex Regional Pain Syndrome - Drugs in Development by Stages, Target, MoA, RoA, Mol, provides an overview of the Complex Regional Pain Syndrome (Central Nervous System) pipeline landscape.

Complex regional pain syndrome (CRPS) is a chronic pain condition that most often affects one limb usually after an injury. CRPS is divided into two types: CRPS-I (Individuals without a confirmed nerve injury) and CRPS-II (when there is an associated, confirmed nerve injury). Symptoms include stiffness in affected joints, changes in nail and hair growth patterns, dystonia and abnormal sweating pattern. Treatment includes bisphosphonates, non-steroidal anti-inflammatory drugs, opioids and local anesthetic creams.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Complex Regional Pain Syndrome - Drugs in Development by Stages, Target, MoA, RoA, Mol, provides comprehensive information on the therapeutics under development for Complex Regional Pain Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Complex Regional Pain Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Phase 0 and Preclinical stages are 3, 1 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Complex Regional Pain Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Complex Regional Pain Syndrome (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Complex Regional Pain Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Complex Regional Pain Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Complex Regional Pain Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Complex Regional Pain Syndrome (Central Nervous System)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Complex Regional Pain Syndrome (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Complex Regional Pain Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Overview
Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Companies Involved in Therapeutics Development
AbbVie Inc
Bexson Biomedical Inc
Bio-Pharm Solutions Co Ltd
Biohaven Pharmaceutical Holding Company Ltd
iX Biopharma Ltd
NeuroTherpia Inc
PharmaTher Holdings Ltd
Soin Therapeutics LLC
Tetra Bio-Pharma Inc
Tryp Therapeutics Inc
Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Drug Profiles
ADD-457023 - Drug Profile
Product Description
Mechanism Of Action
BHV-5000 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ketamine - Drug Profile
Product Description
Mechanism Of Action
History of Events
ketamine - Drug Profile
Product Description
Mechanism Of Action
History of Events
ketamine - Drug Profile
Product Description
Mechanism Of Action
History of Events
naltrexone - Drug Profile
Product Description
Mechanism Of Action
History of Events
NTRX-07 - Drug Profile
Product Description
Mechanism Of Action
onabotulinumtoxin A - Drug Profile
Product Description
Mechanism Of Action
History of Events
PPP-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules for Pain - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Drug Profile
Product Description
Mechanism Of Action
TRP-8803 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Dormant Projects
Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Discontinued Products
Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Product Development Milestones
Featured News & Press Releases
Dec 27, 2021: Soin Therapeutics completes formulation development of novel low dose naltrexone tablet to treat complex regional pain syndrome
Oct 21, 2021: Tetra Bio-Pharma receives positive opinion for orphan drug designation for QIXLEEF from the European Medicines Agency
Oct 13, 2021: PharmaTher granted FDA orphan drug designation for ketamine to treat complex regional pain syndrome
Sep 09, 2021: FDA grants orphan drug status to Soin Therapeutics for low dose naltrexone (LDN) to treat complex regional pain syndrome (CRPS)
Apr 29, 2021: Bexson Biomedical granted USPTO patent on proprietary Ketamine formulation
Oct 08, 2019: Bexson Biomedical's Chief Scientific Officer speaks to ketamine leaders at ASKP conference
Feb 05, 2019: Tetra Bio-Pharma redefines quality standards for pharmaceutical grade cannabis-derived products
Mar 14, 2018: Tetra Bio-Pharma Announces FDA Orphan Drug Designation for PPP001 in Treatment of Complex Regional Pain Syndrome
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Pipeline by AbbVie Inc, 2022
Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Pipeline by Bexson Biomedical Inc, 2022
Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Pipeline by Bio-Pharm Solutions Co Ltd, 2022
Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, 2022
Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Pipeline by iX Biopharma Ltd, 2022
Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Pipeline by NeuroTherpia Inc, 2022
Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Pipeline by PharmaTher Holdings Ltd, 2022
Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Pipeline by Soin Therapeutics LLC, 2022
Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Pipeline by Tetra Bio-Pharma Inc, 2022
Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Pipeline by Tryp Therapeutics Inc, 2022
Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Dormant Projects, 2022
Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy), 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022